Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II Study
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2023-06, Vol.41 (S2), p.400-400 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 400 |
|---|---|
| container_issue | S2 |
| container_start_page | 400 |
| container_title | Hematological oncology |
| container_volume | 41 |
| creator | Choi, Y. S. Song, G. Baek, D. W. Yoon, S. E. Kang, K. Yhim, H. Oh, S. Y. Jeong, S. H. Kim, S. J. Kim, H. J. Do, Y. R. Yang, D. |
| description | |
| doi_str_mv | 10.1002/hon.3164_292 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3089984220</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3089984220</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1494-1eceb73e9cfd2844bede681d0170deaa65b3905540be4ba2b1a23ff05e3f90f73</originalsourceid><addsrcrecordid>eNp9kcFuEzEQhi0EEqFw4wEsce22Y3s3WXOropaulLZRWs6WvTtWXG3sYHsV9sYj8Ba8F0_ChoC4cZoZ_Z_-X5qfkPcMLhgAv9wGfyHYvFRc8hdkxkDKgsFcviQz4Iu6AC74a_ImpWeASYN6Rn40Jg7ZeWeo83QZdsZ5nV3w9ODyljY2JKt3rsNzep3DPqTfq_Yd3bg8fHU7behN6PtwwI6akf6zu9POZ_Tat0ifthj1fjxGrCd39Dmd_DeXm5_fvq-X94-rj_SK3g19du0kY6TrrU5Im4Y-5qEb35JXVvcJ3_2ZZ-TzzfXT8rZYPXxqlleromWlLAuGLZqFQNnajtdlabDDec06YAvoUOt5ZYSEqirBYGk0N0xzYS1UKKwEuxBn5MPJdx_DlwFTVs9hiH6KVAJqKeuSc5io8xPVxpBSRKv2cXpFHBUDdaxCTVWov1VMeHXCD67H8b-sun24P47jLX4BlY6PwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3089984220</pqid></control><display><type>article</type><title>Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II Study</title><source>Wiley Journals</source><creator>Choi, Y. S. ; Song, G. ; Baek, D. W. ; Yoon, S. E. ; Kang, K. ; Yhim, H. ; Oh, S. Y. ; Jeong, S. H. ; Kim, S. J. ; Kim, H. J. ; Do, Y. R. ; Yang, D.</creator><creatorcontrib>Choi, Y. S. ; Song, G. ; Baek, D. W. ; Yoon, S. E. ; Kang, K. ; Yhim, H. ; Oh, S. Y. ; Jeong, S. H. ; Kim, S. J. ; Kim, H. J. ; Do, Y. R. ; Yang, D.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.3164_292</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Etoposide ; Ifosfamide ; Rituximab</subject><ispartof>Hematological oncology, 2023-06, Vol.41 (S2), p.400-400</ispartof><rights>2023 The Authors. Hematological Oncology published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.3164_292$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.3164_292$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Choi, Y. S.</creatorcontrib><creatorcontrib>Song, G.</creatorcontrib><creatorcontrib>Baek, D. W.</creatorcontrib><creatorcontrib>Yoon, S. E.</creatorcontrib><creatorcontrib>Kang, K.</creatorcontrib><creatorcontrib>Yhim, H.</creatorcontrib><creatorcontrib>Oh, S. Y.</creatorcontrib><creatorcontrib>Jeong, S. H.</creatorcontrib><creatorcontrib>Kim, S. J.</creatorcontrib><creatorcontrib>Kim, H. J.</creatorcontrib><creatorcontrib>Do, Y. R.</creatorcontrib><creatorcontrib>Yang, D.</creatorcontrib><title>Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II Study</title><title>Hematological oncology</title><subject>Etoposide</subject><subject>Ifosfamide</subject><subject>Rituximab</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kcFuEzEQhi0EEqFw4wEsce22Y3s3WXOropaulLZRWs6WvTtWXG3sYHsV9sYj8Ba8F0_ChoC4cZoZ_Z_-X5qfkPcMLhgAv9wGfyHYvFRc8hdkxkDKgsFcviQz4Iu6AC74a_ImpWeASYN6Rn40Jg7ZeWeo83QZdsZ5nV3w9ODyljY2JKt3rsNzep3DPqTfq_Yd3bg8fHU7behN6PtwwI6akf6zu9POZ_Tat0ifthj1fjxGrCd39Dmd_DeXm5_fvq-X94-rj_SK3g19du0kY6TrrU5Im4Y-5qEb35JXVvcJ3_2ZZ-TzzfXT8rZYPXxqlleromWlLAuGLZqFQNnajtdlabDDec06YAvoUOt5ZYSEqirBYGk0N0xzYS1UKKwEuxBn5MPJdx_DlwFTVs9hiH6KVAJqKeuSc5io8xPVxpBSRKv2cXpFHBUDdaxCTVWov1VMeHXCD67H8b-sun24P47jLX4BlY6PwA</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Choi, Y. S.</creator><creator>Song, G.</creator><creator>Baek, D. W.</creator><creator>Yoon, S. E.</creator><creator>Kang, K.</creator><creator>Yhim, H.</creator><creator>Oh, S. Y.</creator><creator>Jeong, S. H.</creator><creator>Kim, S. J.</creator><creator>Kim, H. J.</creator><creator>Do, Y. R.</creator><creator>Yang, D.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>202306</creationdate><title>Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II Study</title><author>Choi, Y. S. ; Song, G. ; Baek, D. W. ; Yoon, S. E. ; Kang, K. ; Yhim, H. ; Oh, S. Y. ; Jeong, S. H. ; Kim, S. J. ; Kim, H. J. ; Do, Y. R. ; Yang, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1494-1eceb73e9cfd2844bede681d0170deaa65b3905540be4ba2b1a23ff05e3f90f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Etoposide</topic><topic>Ifosfamide</topic><topic>Rituximab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Y. S.</creatorcontrib><creatorcontrib>Song, G.</creatorcontrib><creatorcontrib>Baek, D. W.</creatorcontrib><creatorcontrib>Yoon, S. E.</creatorcontrib><creatorcontrib>Kang, K.</creatorcontrib><creatorcontrib>Yhim, H.</creatorcontrib><creatorcontrib>Oh, S. Y.</creatorcontrib><creatorcontrib>Jeong, S. H.</creatorcontrib><creatorcontrib>Kim, S. J.</creatorcontrib><creatorcontrib>Kim, H. J.</creatorcontrib><creatorcontrib>Do, Y. R.</creatorcontrib><creatorcontrib>Yang, D.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Y. S.</au><au>Song, G.</au><au>Baek, D. W.</au><au>Yoon, S. E.</au><au>Kang, K.</au><au>Yhim, H.</au><au>Oh, S. Y.</au><au>Jeong, S. H.</au><au>Kim, S. J.</au><au>Kim, H. J.</au><au>Do, Y. R.</au><au>Yang, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II Study</atitle><jtitle>Hematological oncology</jtitle><date>2023-06</date><risdate>2023</risdate><volume>41</volume><issue>S2</issue><spage>400</spage><epage>400</epage><pages>400-400</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.3164_292</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2023-06, Vol.41 (S2), p.400-400 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_journals_3089984220 |
| source | Wiley Journals |
| subjects | Etoposide Ifosfamide Rituximab |
| title | Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A11%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ibrutinib%20in%20Combination%20with%20Ifosfamide,%20Etoposide,%20and%20Rituximab%20Followed%20by%20Ibrutinib%20Maintenance%20Therapy%20in%20Patients%20with%20R/R%E2%80%90PCNSL:%20A%20Multicenter%20Phase%20II%20Study&rft.jtitle=Hematological%20oncology&rft.au=Choi,%20Y.%20S.&rft.date=2023-06&rft.volume=41&rft.issue=S2&rft.spage=400&rft.epage=400&rft.pages=400-400&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.3164_292&rft_dat=%3Cproquest_cross%3E3089984220%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3089984220&rft_id=info:pmid/&rfr_iscdi=true |